Experts are reclaiming the claims of two Israeli scientists who have found a cure for cancer. The original claim, published on Tuesdays Jerusalem PostIt has been viral, reaching millions of Internet views while holding international holders.
"We must keep in mind that this is far from being proven as an effective treatment for people with cancer, much less a cure," wrote Dr. J. Leonard Lichtenfeld, deputy director for the national office of the American Cancer Society. blog
Lichtenfeld said that the article was simply a news based on the information provided by the researchers, but that the investigation has not yet been published in the scientific literature "where it would be subject to review, support and / or criticism of knowledge colleagues."
Lichtenfeld also said that he spoke with colleagues who believe that the technology presented by Accelerated Evolution Biotechnologies Ltd. (AEBi) could be very powerful, but also harder to work than the company kept as the research in vitro progressed to animal testing human.
"If this group is only beginning clinical trials, it is possible that they have some difficult experiments ahead," he wrote.
In the history of Tuesday, the president of the board of directors of AEBi, Dan Aridor and its general director, Dr. Ilan Morad, said that their treatment, which they call MuTaTo (multi-objective toxin), is essentially the scale of a carcinogenic antibiotic: an interruption of the highest order technology. In the story, Morad said the company has completed its first exploration rat experiment plus several tests in vitro. AEBi, he said, was at the peak of starting a series of clinical trials that could be completed within a few years and would make the treatment available in specific cases.
Despite his enthusiasm, publications in the United States and Israel rejected the report, insisting that, as Victoria Forster stated, a "categorically false" Forbes medical care reporter.
Forester cited Dr. Benjamin G. Neel, a professor of medicine from the Faculty of Medicine at NYU, said that anything proven in mice should undergo tests in other animal species, formulate and pass the administration in the clinical trials of Phase I in humans.
Forester concluded that "based on what they have sent to the media," AEBi will not be cured for cancer, and their claims are "highly irresponsible and even cruel."
O Post He presented the criticisms of Aridor and Morad, who have said that "it will be available for testing in humans in one year, and will be a complete cure, for the first time, a complete cure."
Morad said that with the correct budget, it will not take much more than a year to reach clinical trials and "when we get to clinical trials, we can treat patients."
"I hear many rejection that it is not possible to develop a drug so fast. But we have not said that we are going to develop the drug and get its approval," continued Morad. "We have said we can treat and heal people."
The team said the company presented itself and was the subject of peer review, that is, at three conferences of the Drug Discovery Innovation Program in Munich, Boston and Frankfurt. The main pharmaceutical companies attend to these events, they said, including representatives of industry leaders Zoetic, Ultragneyx and Sundia, for example.
AEB maintained that they have not published in a scientific journal – another critical point – because they are a privately owned company and are still in the process of generating final patents on their intellectual property. They said they have patents on their platform in the European Union and Israel, and expect to have one in the United States soon.
O Post It reached about 10 additional scientists and researchers, including hospitals and oncologists, most of whom did not want to comment on the record and felt that AEB's claims were too far away.
But Dr. Moshik Cohen-Kutner, co-founder and CEO of Omnix Medical, said that although he does not know the company enough to comment on whether they have a cure for cancer, "I know that peptide-based drugs are very promising."
"AEBi technology can be a cure for cancer due to the personalized route that seeks to use selective peptides," he continued. "It is only recently that the technology that involves peptides has reached a point where it is relatively easy to investigate. Peptides have the capacity to cure human diseases."
He told the Post that "solidly and scientifically sound" projects can take between one and two years to get mice tests for human trials, as long as there is adequate funding.
However, as Lichtenfeld maintained in his blog post: "We hope that this approach … takes fruit and is successful. At the same time, we should always offer a cautious note that the process of obtaining this treatment from the mouse to man does not It's always a simple and easy trip. "
The Jerusalem Post will continue with AEBi in 12 months.
Join Jerusalem Post Premium Plus now for only $ 5 and update your experience with a website without ads and exclusive content. Click here >>